Even the response to endocrine therapy is related to the level and uniformity of ER expression: tumors strongly expressing ER in the majority of tumor cells show a better outcome than ER-heterogeneous tumors [45,46] whereas intra-metastatic ER heterogeneity has been reported as an independent predictor of poor patient survival [47]. This evidence concerns the gene ESR1 and neoplasm.